Evidence map›Paper›PMID 34558968›Full record

ArticleEnvironmental health perspectives2021

Key Characteristics of Cardiovascular Toxicants.

Lars Lind, Jesus A Araujo, Aaron Barchowsky, Scott Belcher, Brian R Berridge, Nipavan Chiamvimonvat, Weihsueh A Chiu, Vincent J Cogliano, Sarah Elmore, Aimen K Farraj and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Environmental health perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. A workflow for human health hazard evaluation using transcriptomic data and Key Characteristics-based gene sets.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. The key characteristics concept.Current opinion in toxicology · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 1 country.

Lars LindDepartment of Medical Sciences, Clinical Epidemiology, University of Uppsala, Sweden.
Jesus A AraujoDivision of Cardiology, David Geffen School of Medicine at University of California Los Angeles (UCLA), UCLA, Los Angeles, California, USA.
Aaron BarchowskyDepartment of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, USA.
Scott BelcherDepartment of Biological Sciences, North Carolina State University, North Carolina, USA.
Brian R BerridgeDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA.
Nipavan ChiamvimonvatDepartment of Internal Medicine, University of California, Davis, Davis, California, USA.
Weihsueh A ChiuCollege of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
Vincent J CoglianoOffice of Environmental Health Hazard Assessment, California Environmental Protection Agency (EPA), Oakland, California, USA.
Sarah ElmoreOffice of Environmental Health Hazard Assessment, California Environmental Protection Agency (EPA), Oakland, California, USA.
Aimen K FarrajPublic Health and Integrated Toxicology Division, Center for Public Health and Environmental Assessment, U.S. EPA, Research Triangle Park, North Carolina, USA.
Aldrin V GomesDepartment of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, Davis, California, USA.
Cliona M McHaleDivision of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California, USA.
Kathleen B Meyer-TamakiSangamo Therapeutics, Brisbane, California, USA.
Nikki Gillum PosnackChildren's National Heart Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Hugo M VargasTranslational Safety & Bioanalytical Sciences, Amgen, Inc., Thousand Oaks, California, USA.
Xi YangDivision of Pharmacology and Toxicology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Lauren ZeiseOffice of Environmental Health Hazard Assessment, California Environmental Protection Agency (EPA), Oakland, California, USA.
Changcheng ZhouDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, California, USA.
Martyn T SmithDivision of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California, USA.
California Environmental Protection Agency · USUniversity of California, Berkeley · USUniversity of California, Davis · USAmgen (United States) · USCenter for Drug Evaluation and Research · USChildren's National · USEnvironmental Protection Agency · USNational Institutes of Health · USNorth Carolina State University · USSangamo BioSciences (United States) · USTexas A&M University · USUniversity of California, Los Angeles · USUniversity of California, Riverside · USUniversity of Pittsburgh · US

Funding

Training CoreP42ES004705 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI SMITH, MARTYN T · 1987 to 2025
$74.6M
Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
Single cell, multi-parametric high throughput platform to classify endocrine disruptor potential of mixturesP42ES027704 · NIEHS · TEXAS A&M UNIVERSITY · PI Ivan Rusyn · 2017 to 2026
$21.2M
Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Natalie M Johnson · 2019 to 2026
$13.0M
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?R01HL139472 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI Nikki Gillum Posnack · 2018 to 2026
$5.2M
Endocrine disruptor mediated activation of PXR causes dyslipidemia and atherosclerosisR01ES023470 · NIEHS · UNIVERSITY OF KENTUCKY · PI ZHOU, CHANGCHENG · 2013 to 2022
$2.7M
Role of Intestinal Microbiota in Dyslipidemia and Atherosclerosis Induced by Ambient Ultrafine ParticlesR01ES029395 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARAUJO, JESUS ANTONIO, HSIAI, TZUNG K · 2018 to 2022
$2.2M
Interplay Between Macrophages, Lipid Oxidation and the Nrf2/HO-1 Axis in the Cardiometabolic Toxicity Induced by Ultrafine ParticlesR01ES032806 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARAUJO, JESUS ANTONIO · 2021 to 2025
$2.0M
Role of IKKβ in obesity and atherosclerosisR01HL131925 · NHLBI · UNIVERSITY OF KENTUCKY · PI ZHOU, CHANGCHENG · 2016 to 2019
$1.5M
A novel mechanism for ART-associated dyslipidemia and atherosclerosisR01HL123358 · NHLBI · UNIVERSITY OF KENTUCKY · PI ZHOU, CHANGCHENG · 2015 to 2018
$1.5M
NHLBI NIH HHS R01 HL123358NHLBI NIH HHS R01 HL131925NHLBI NIH HHS R01 HL139472NIEHS NIH HHS P30 ES029067NIEHS NIH HHS P42 ES004699NIEHS NIH HHS P42 ES004705NIEHS NIH HHS P42 ES027704NIEHS NIH HHS R01 ES023470NIEHS NIH HHS R01 ES029395NIEHS NIH HHS R01 ES032806
6 · The paper itself

Abstract

backgroundThe concept of chemical agents having properties that confer potential hazard called key characteristics (KCs) was first developed to identify carcinogenic hazards. Identification of KCs of cardiovascular (CV) toxicants could facilitate the systematic assessment of CV hazards and understanding of assay and data gaps associated with current approaches.

objectivesWe sought to develop a consensus-based synthesis of scientific evidence on the KCs of chemical and nonchemical agents known to cause CV toxicity along with methods to measure them.

methodsAn expert working group was convened to discuss mechanisms associated with CV toxicity.

resultsThe group identified 12 KCs of CV toxicants, defined as exogenous agents that adversely interfere with function of the CV system. The KCs were organized into those primarily affecting cardiac tissue (numbers 1-4 below), the vascular system (5-7), or both (8-12), as follows: 1) impairs regulation of cardiac excitability, 2) impairs cardiac contractility and relaxation, 3) induces cardiomyocyte injury and death, 4) induces proliferation of valve stroma, 5) impacts endothelial and vascular function, 6) alters hemostasis, 7) causes dyslipidemia, 8) impairs mitochondrial function, 9) modifies autonomic nervous system activity, 10) induces oxidative stress, 11) causes inflammation, and 12) alters hormone signaling. DISCUSSION: These 12 KCs can be used to help identify pharmaceuticals and environmental pollutants as CV toxicants, as well as to better understand the mechanistic underpinnings of their toxicity. For example, evidence exists that fine particulate matter [PM

Indexed as

Air PollutantsAir PollutionEnvironmental PollutantsCarcinogensHazardous SubstancesParticulate MatterAir PollutantsCarcinogensEnvironmental PollutantsHazardous SubstancesParticulate Matter

Identifiers

PMID34558968
PMCPMC8462506
OpenAlexW3201417477

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.